These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17436027)

  • 21. Outcomes measurement: health state preferences and economic evaluation.
    Oldridge NB
    Assist Technol; 1996; 8(2):94-102. PubMed ID: 10163933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
    Beresniak A; Dupont D
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European School of Oncology Advisory report to the Commission of the European Communities for the "Europe Against Cancer Programme" cost-effectiveness in cancer care.
    Williams C; Coyle D; Gray A; Hutton J; Jefferson T; Karlsson G; Kesteloot K; Uyl-de Groot C; Wait S
    Eur J Cancer; 1995; 31A(9):1410-24. PubMed ID: 7577064
    [No Abstract]   [Full Text] [Related]  

  • 24. E-health development policies in new member states in Central Europe.
    Duplaga M
    World Hosp Health Serv; 2007; 43(2):34-8. PubMed ID: 17894192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh.
    Teerawattananon Y; Tantivess S; Yamabhai I; Tritasavit N; Walker DG; Cohen JT; Neumann PJ
    Health Res Policy Syst; 2016 Dec; 14(1):86. PubMed ID: 27912780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International practices in health technology assessment and public financing of digital health technologies: recommendations for Hungary.
    Mezei F; Horváth K; Pálfi M; Lovas K; Ádám I; Túri G
    Front Public Health; 2023; 11():1197949. PubMed ID: 37719722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health technology assessment and health care in the European Union.
    Banta D; Oortwijn W
    Int J Technol Assess Health Care; 2000; 16(2):626-35. PubMed ID: 10932427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hungary health system review.
    Gaal P; Szigeti S; Csere M; Gaskins M; Panteli D
    Health Syst Transit; 2011; 13(5):1-266. PubMed ID: 22394651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The crisis as catalyst for reframing health care policies in the European Union.
    Helderman JK
    Health Econ Policy Law; 2015 Jan; 10(1):45-59. PubMed ID: 25662196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. History of health technology assessment in Hungary.
    Gulácsi L; Brodszky V; Péntek M; Varga S; Vas G; Boncz I
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():120-6. PubMed ID: 19500441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Global cost-effectiveness of cataract surgery.
    Lansingh VC; Carter MJ; Martens M
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries.
    Stargardt T
    Health Econ; 2008 Jan; 17(1 Suppl):S9-20. PubMed ID: 18186038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EU Country Specific Recommendations for health systems in the European Semester process: trends, discourse and predictors.
    Azzopardi-Muscat N; Clemens T; Stoner D; Brand H
    Health Policy; 2015 Mar; 119(3):375-83. PubMed ID: 25650138
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Indirect costs in health technology assessment].
    Jakubczyk M; Wrona W; Macioch T; Golicki D; Niewada M; Hermanowski T
    Pol Merkur Lekarski; 2010 Jan; 28(163):42-5. PubMed ID: 20369723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ['European primary care': a visionary report of the Dutch Health Council on primary health care in the European Union].
    Thomas S
    Ned Tijdschr Geneeskd; 2005 May; 149(20):1086-8. PubMed ID: 15932132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.
    Ades F; Senterre C; Zardavas D; de Azambuja E; Popescu R; Parent F; Piccart M
    Eur J Cancer; 2014 Dec; 50(18):3089-97. PubMed ID: 25446375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey.
    Tordrup D; Angelis A; Kanavos P
    Appl Health Econ Health Policy; 2013 Dec; 11(6):639-52. PubMed ID: 24129648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Guidelines for health-economic evaluations in Austria].
    Walter E; Zehetmayr S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):628-32. PubMed ID: 17211768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.